EVMN (Evommune) Operating Margin %: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EVMN Evommune Inc EVMN
10 GF Score
Price $14.49
! 2 Warning Signs
View Full Analysis

What is Evommune Operating Margin %?

Evommune EVMN +2.62% 10 Operating Margin % is 0.00% as of Jun. 2026. GuruFocus rates EVMN with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 943 Biotechnology companies, Evommune ranks worse than 79.11% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Evommune's Operating Income for the three months ended in Jun. 2026 was $-34.90 Mil. Evommune's Revenue for the three months ended in Jun. 2026 was $0.00 Mil. Therefore, Evommune's Operating Margin % for the quarter that ended in Jun. 2026 was 0.00%.

The historical rank and industry rank for Evommune's Operating Margin % or its related term are showing as below:

EVMN' s Operating Margin % Range Over the Past 10 Years
Min: -1018.93   Med: -757   Max: -623.62
Current: -1018.93


EVMN's Operating Margin % is ranked worse than
79.11% of 943 companies
in the Biotechnology industry
Industry Median: -83.62 vs EVMN: -1018.93

Evommune's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Evommune's Operating Income for the three months ended in Jun. 2026 was $-34.90 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was $-101.89 Mil.


Evommune  (NYSE:EVMN) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Evommune Operating Margin % Related Terms


Evommune Operating Margin % Historical Data

* Premium members only.

The historical data trend for Evommune's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evommune Operating Margin % Chart

Evommune Annual Data
Trend Dec23 Dec24 Dec25
Operating Margin %
-757.00 -1,000.19 -623.62

Evommune Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 -133.28 0.00 0.00 0.00

EVMN vs OCGN, PBYI, LRMR: Operating Margin % Comparison

For the Biotechnology subindustry, Evommune's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evommune Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evommune's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Evommune's Operating Margin % falls into.


EVMN
10GF Score
Evommune Inc EVMN
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evommune Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Evommune's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-81.071 / 13
=-623.62 %

Evommune's Operating Margin % for the quarter that ended in Jun. 2026 is calculated as

Operating Margin %=Operating Income (Q: Jun. 2026 ) / Revenue (Q: Jun. 2026 )
=-34.895 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 0.00% mean?
Evommune (EVMN) has a Operating Margin % of 0.00% as of Jun. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Evommune and its competitors. According to the industry distribution chart, Evommune ranks #746 out of 943 companies in the Biotechnology industry, placing it in the top 79.1%.
Is Evommune's Operating Margin % too high?
Evommune's current Operating Margin % is 0.00%. Based on the distribution chart, Evommune ranks #746 out of 943 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Evommune has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Evommune's Operating Margin % compare to OCGN and PBYI?
According to the Biotechnology industry distribution chart, Evommune ranks #746 out of 943 companies for Operating Margin %. This places Evommune in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Evommune and its competitors. Evommune's current Operating Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evommune stock overvalued right now?
Evommune (EVMN) has a current Operating Margin % of 0.00%. The current Operating Margin % is 0.00%. Evommune's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Evommune (EVMN), the current Operating Margin % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evommune Business Description

Address 1841 Page Mill Road, Suite 100, Palo Alto, CA, USA, 94304
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
10GF Score

Get the complete analysis for EVMN

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.49
Price